ArticleArchives of osteoporosis2026
Pregnancy and lactation-associated osteoporosis: insights from an online self-reported patient survey.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy and lactation-associated osteoporosis (PLO) is a rare yet debilitating cause of vertebral fractures in young women. Despite its significant clinical impact, PLO remains underdiagnosed, and data on its risk factors and management are limited. In our cohort, vitamin D deficiency, heparin exposure and a family history of osteoporosis emerged as key risk factors. Among anti-osteoporotic medications, teriparatide was the most commonly prescribed, followed by denosumab, alendronate and others. PURPOSE: This study aimed to characterize the clinical features of women with PLO and to identify key risk factors using self-reported data from an online patient support group.
methodsA cross-sectional study was conducted among 52 women diagnosed with PLO, identified via a patient support group on WhatsApp. Data were collected through an online survey assessing demographics, fracture characteristics, bone mineral density (BMD), treatment approaches, and potential risk factors. Participants were stratified into two groups (with vs. without fractures) for comparative analysis.
resultsThe mean age of participants was 33.8 ± 4.7 years. Fractures occurred in 78.8% of participants, predominantly involving the spine (90.2%). The mean T-scores were -2.9 ± 0.8 at the spine and -1.8 ± 1.3 at the femoral neck. Key reported risk factors were vitamin D deficiency, heparin use during pregnancy, and a family history of osteoporosis. Women with fractures reported significantly higher levels of physical activity during pregnancy (p = 0.026). Anti-osteoporotic medications were used by 58% of participants, and teriparatide was the most frequently prescribed agent (44.8%).
conclusionPLO is an underrecognized and disabling complication of pregnancy, most often resulting in vertebral fractures. Greater clinical awareness, targeted screening, and individualized management are crucial to reduce preventable maternal morbidity in high-risk women.
Indexed as
Identifiers
42234275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.